Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTOR NYSE:CYBN NASDAQ:MOLN NASDAQ:OKUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTORCitius Oncology$1.84-3.7%$2.06$0.55▼$6.19$144.20M31.19 million shs109,604 shsCYBNCybin$6.01-1.3%$7.29$4.81▼$13.88$141.78M0.68351,875 shs570,049 shsMOLNMolecular Partners$3.76+0.9%$3.70$3.36▼$7.60$151.63M1.16,275 shs1,076 shsOKUROnKure Therapeutics$2.39-2.4%$2.47$1.70▼$20.00$32.34M0.42107,890 shs24,873 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTORCitius Oncology0.00%+1.60%+13.02%+37.41%+17.18%CYBNCybin0.00%-9.51%-13.74%-24.25%+1,550.41%MOLNMolecular Partners0.00%+2.68%+3.99%-4.42%-29.58%OKUROnKure Therapeutics0.00%-10.91%-3.16%-5.77%+244,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTORCitius Oncology$1.84-3.7%$2.06$0.55▼$6.19$144.20M31.19 million shs109,604 shsCYBNCybin$6.01-1.3%$7.29$4.81▼$13.88$141.78M0.68351,875 shs570,049 shsMOLNMolecular Partners$3.76+0.9%$3.70$3.36▼$7.60$151.63M1.16,275 shs1,076 shsOKUROnKure Therapeutics$2.39-2.4%$2.47$1.70▼$20.00$32.34M0.42107,890 shs24,873 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTORCitius Oncology0.00%+1.60%+13.02%+37.41%+17.18%CYBNCybin0.00%-9.51%-13.74%-24.25%+1,550.41%MOLNMolecular Partners0.00%+2.68%+3.99%-4.42%-29.58%OKUROnKure Therapeutics0.00%-10.91%-3.16%-5.77%+244,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTORCitius Oncology 2.00Hold$3.0060.43% UpsideCYBNCybin 3.25Buy$85.001,329.77% UpsideMOLNMolecular Partners 3.00Buy$8.00111.92% UpsideOKUROnKure Therapeutics 3.14Buy$32.331,266.58% UpsideCurrent Analyst Ratings BreakdownLatest OKUR, CYBN, CTOR, and MOLN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025MOLNMolecular PartnersJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$4.50 ➝ $4.008/26/2025OKUROnKure TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.008/13/2025OKUROnKure TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/8/2025CYBNCybinCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$73.00 ➝ $70.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTORCitius OncologyN/AN/AN/AN/A$0.64 per shareN/ACYBNCybinN/AN/AN/AN/A$10.83 per shareN/AMOLNMolecular Partners$5.65M26.98N/AN/A$3.99 per share0.95OKUROnKure TherapeuticsN/AN/AN/AN/A$7.78 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTORCitius OncologyN/AN/A0.00∞N/AN/A-51.93%-22.17%N/ACYBNCybin-$57.88M-$4.60N/AN/AN/AN/A-37.58%-36.59%N/AMOLNMolecular Partners-$61.39M-$2.08N/AN/AN/AN/A-50.66%-45.13%10/30/2025 (Estimated)OKUROnKure Therapeutics-$52.67M-$4.80N/AN/AN/AN/A-60.52%-55.43%11/6/2025 (Estimated)Latest OKUR, CYBN, CTOR, and MOLN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/25/2025H1 2025MOLNMolecular Partners-$0.53-$0.67-$0.14-$0.67N/AN/A8/12/2025Q2 2025OKUROnKure Therapeutics-$1.23-$1.14+$0.09-$1.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTORCitius OncologyN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTORCitius Oncology0.120.350.02CYBNCybinN/A24.2424.24MOLNMolecular PartnersN/A9.359.35OKUROnKure TherapeuticsN/A11.1311.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTORCitius Oncology70.52%CYBNCybin17.94%MOLNMolecular Partners26.55%OKUROnKure Therapeutics90.98%Insider OwnershipCompanyInsider OwnershipCTORCitius Oncology4.57%CYBNCybin15.00%MOLNMolecular Partners5.93%OKUROnKure Therapeutics17.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTORCitius OncologyN/A78.37 million74.79 millionN/ACYBNCybin5023.59 million17.96 millionNot OptionableMOLNMolecular Partners18040.38 million37.98 millionNot OptionableOKUROnKure TherapeuticsN/A13.53 million11.11 millionN/AOKUR, CYBN, CTOR, and MOLN HeadlinesRecent News About These CompaniesCompanies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite RiskyAugust 19, 2025 | finance.yahoo.comCompanies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite RiskyAugust 19, 2025 | finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and AbCellera Biologics (ABCL)August 15, 2025 | theglobeandmail.comOnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)August 12, 2025 | msn.comOnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business UpdateAugust 12, 2025 | globenewswire.comOKUR OnKure Therapeutics, Inc.June 12, 2025 | seekingalpha.comBuy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial PositionJune 3, 2025 | tipranks.comInsider Selling: OnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Sells 1,813,439 Shares of StockMay 20, 2025 | insidertrades.comOnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Cormorant Asset Management, Lp Sells 24,300 SharesMay 15, 2025 | insidertrades.comMajor Shareholder Sells Thousands of OnKure Therapeutics Shares!May 14, 2025 | tipranks.comPromising Developments and Positive Trial Results Reinforce Buy Rating for OnKure TherapeuticsMay 9, 2025 | tipranks.comOnKure increased R&D spending in 1Q with drug trials underwayMay 7, 2025 | bizwest.comBOnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | finanznachrichten.deOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | OKUR ...May 6, 2025 | gurufocus.comOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | gurufocus.comOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | globenewswire.comOnKure Therapeutics (OKUR) Receives Outperform Rating from Evercore ISI | OKUR Stock NewsApril 30, 2025 | gurufocus.comOnKure Therapeutics, Inc. Class A Common Stock (OKUR) ChartsApril 16, 2025 | nasdaq.comWhy OnKure Therapeutics, Inc.’s (OKUR) Stock Is Down 19.54%April 5, 2025 | aaii.comAOnKure Therapeutics price target lowered to $34 from $40 at H.C. WainwrightMarch 18, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesJackson Hole 2025: Fed’s Signal Could Shift Stocks FastBy Chris Markoch | August 20, 2025Should You Join Buffett and Invest in Constellation Brands?By Jordan Chussler | August 22, 2025Small Cap, Big Potential: 3 Tech Disruptors You Should Know AboutBy Nathan Reiff | August 22, 2025Is It Too Late to Jump on the Nuclear Bandwagon? By Jordan Chussler | August 25, 2025Smaller Industrials Names Seeing Surging Growth: Here's WhyBy Nathan Reiff | August 30, 2025OKUR, CYBN, CTOR, and MOLN Company DescriptionsCitius Oncology NASDAQ:CTOR$1.84 -0.07 (-3.66%) Closing price 04:00 PM EasternExtended Trading$1.85 +0.01 (+0.54%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Cybin NYSE:CYBN$6.01 -0.08 (-1.31%) Closing price 04:00 PM EasternExtended Trading$6.02 +0.00 (+0.08%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.Molecular Partners NASDAQ:MOLN$3.76 +0.04 (+0.94%) Closing price 03:56 PM EasternExtended Trading$3.74 -0.01 (-0.40%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.OnKure Therapeutics NASDAQ:OKUR$2.39 -0.06 (-2.45%) Closing price 04:00 PM EasternExtended Trading$2.38 -0.01 (-0.42%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
